Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Revenue (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Revenue for 11 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 143.99% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.4 million through Dec 2025, down 49.5% year-over-year, with the annual reading at $40.4 million for FY2025, 49.53% down from the prior year.
  • Revenue hit $15.4 million in Q4 2025 for Voyager Therapeutics, up from $13.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $150.5 million in Q1 2023 to a low of -$1.5 million in Q4 2022.
  • Historically, Revenue has averaged $22.4 million across 5 years, with a median of $6.5 million in 2021.
  • Biggest five-year swings in Revenue: tumbled 105.52% in 2022 and later soared 22769.3% in 2023.
  • Year by year, Revenue stood at $28.1 million in 2021, then plummeted by 105.52% to -$1.5 million in 2022, then surged by 5913.42% to $90.1 million in 2023, then plummeted by 93.01% to $6.3 million in 2024, then surged by 143.99% to $15.4 million in 2025.
  • Business Quant data shows Revenue for VYGR at $15.4 million in Q4 2025, $13.4 million in Q3 2025, and $5.2 million in Q2 2025.